CancerDrs

Head and Neck Cancer clinical trials

300 actively recruiting head and neck cancer trials in the United States. Cancers of the oral cavity, pharynx, larynx, and salivary glands. HPV-driven and smoking-driven subtypes behave differently; trials often stratify on HPV status.

Data from ClinicalTrials.gov · last refreshed · Head and Neck Cancer stats on SEER

61
Phase 1
114
Phase 2
11
Phase 3
4
Phase 4
110
Other

Head and Neck Cancer by the numbers (U.S.)

59,660
Estimated new cases (2025)
12,770
Estimated deaths (2025)
69.5%
5-year relative survival
65
Median age at diagnosis

Source: NCI SEER Cancer Stat Facts

Browse head and neck cancer trials by state

Top trials by phase + site coverage

Phase 2, Phase 3 Recruiting Academic/Other

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…

Sponsor: NRG Oncology
NCT ID: NCT04333537
Locations:
  • University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona

+ 103 more sites in the U.S.

Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Locations:
  • Research Site — Birmingham, Alabama
  • Research Site — Mobile, Alabama
  • Research Site — Anchorage, Alaska

+ 90 more sites in the U.S.

Phase 2, Phase 3 Recruiting Industry

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

Ficerafusp alfa is directed against two targets, Epidermal Growth Factor Receptor (EGFR) and Transforming Growth Factor beta (TGF-β). This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizum…

Sponsor: Bicara Therapeutics
NCT ID: NCT06788990
Locations:
  • Site # 0137 — Birmingham, Alabama
  • Site #0147 — Phoenix, Arizona
  • Site #0107 — La Jolla, California

+ 52 more sites in the U.S.

Phase 3 Recruiting Industry

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

The goal of this study is to understand whether CRB-701, a targeted form of chemotherapy called an anti-body drug conjugate, will work as a treatment for oropharyngeal (throat, tonsil) cancer. In patients who have already received platinum…

Sponsor: Corbus Pharmaceuticals Inc.
NCT ID: NCT07768189
Locations:
  • Clearview Cancer Institute — Huntsville, Alabama
  • The University of Arizona Cancer Center — Tucson, Arizona
  • City of Hope Comprehensive Cancer Center — Duarte, California

+ 35 more sites in the U.S.

Phase 3 Recruiting Industry

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is …

Sponsor: AVEO Pharmaceuticals, Inc.
NCT ID: NCT06064877
Locations:
  • Banner MD Anderson Cancer Center — Gilbert, Arizona
  • The University of Arizona Cancer Center — Tucson, Arizona
  • University of California Los Angeles — Los Angeles, California

+ 25 more sites in the U.S.

Phase 3 Recruiting Network

SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer

This study is being done to answer the following question: Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single…

Sponsor: Canadian Cancer Trials Group
NCT ID: NCT05451004
Locations:
  • City of Hope Corona — Corona, California
  • City of Hope Comprehensive Cancer Center — Duarte, California
  • City of Hope at Irvine Lennar — Irvine, California

+ 25 more sites in the U.S.

Phase 3 Recruiting Industry

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

This is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve,…

Sponsor: Johnson & Johnson Enterprise Innovation Inc.
NCT ID: NCT04892173
Locations:
  • University of Alabama at Birmingham — Birmingham, Alabama
  • City of Hope — Duarte, California
  • University of California at San Diego Moores Cancer Center — La Jolla, California

+ 23 more sites in the U.S.

Phase 3 Recruiting Industry

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…

Sponsor: SOFIE
NCT ID: NCT07217704
Locations:
  • Helios CR Inc./RadNet — Cerritos, California
  • City of Hope National Cancer Center — Duarte, California
  • Hoag Memorial Hospital — Irvine, California

+ 13 more sites in the U.S.

Phase 3 Recruiting Academic/Other

An Imaging Agent (Pafolacianine) for Identifying Lesions in Pediatric Patients With Primary or Metastatic Solid Tumors

This phase III trial studies how well pafolacianine works for identifying cancerous lesions in children and adolescent patients with primary solid tumors or solid tumors that have spread from where they first started (primary site) to othe…

Sponsor: Mayo Clinic
NCT ID: NCT06915727
Locations:
  • Mayo Clinic in Rochester — Rochester, Minnesota
Phase 3 Recruiting Academic/Other

Head and Neck Cancer Study Project in the Geriatric Population

This is a study conducted in patients with a diagnosis of stage IB-IVA squamous cell carcinoma of the head and neck. Patients will have a comprehensive geriatric assessment (CGA) as part of standard assessments. The patients classified as …

Sponsor: Brown University
NCT ID: NCT06998069
Locations:
  • Rhode Island and The Miriam Hospitals — Providence, Rhode Island
Phase 2, Phase 3 Recruiting Academic/Other

99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT

This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to Choline, for a prospective single-center, single-arm study for participants with suspected parathyroid adenoma and negative or equivocal standard of…

Sponsor: Andrei Iagaru
NCT ID: NCT05891769
Locations:
  • Stanford Hospital and Clinics — Stanford, California
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Locations:
  • Mayo Clinic Hospital in Arizona — Phoenix, Arizona
  • University of Arkansas for Medical Sciences — Little Rock, Arkansas
  • Tower Cancer Research Foundation — Beverly Hills, California

+ 227 more sites in the U.S.

Showing 12 of 300 trials. See all on ClinicalTrials.gov

Before you contact a trial site

Trial eligibility criteria are specific and strict. Reading them carefully before calling a site saves time. These guides walk through what to look for.

Medical disclaimer: Information on this page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-19